- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.35 Å
- Oligo State
- homo-trimer
- Ligands
- 3 x JUQ: (1~{S},2~{S})-2-[5-[cyclopropylmethyl(naphthalen-1-yl)amino]-4-methoxy-pyrimidin-2-yl]carbonylcyclopropane-1-carboxylic acid(Non-covalent)
- 3 x NI: NICKEL (II) ION(Non-covalent)
NI.2: 6 residues within 4Å:- Chain A: H.6, H.8
- Chain B: H.6, H.8
- Chain C: H.6, H.8
6 PLIP interactions:2 interactions with chain A, 2 interactions with chain C, 2 interactions with chain B- Metal complexes: A:H.6, A:H.8, C:H.6, C:H.8, B:H.6, B:H.8
NI.9: 2 residues within 4Å:- Chain B: H.3, H.5
2 PLIP interactions:2 interactions with chain B- Metal complexes: B:H.3, B:H.5
NI.18: 2 residues within 4Å:- Chain C: H.3, H.5
2 PLIP interactions:2 interactions with chain C- Metal complexes: C:H.3, C:H.5
- 16 x PLM: PALMITIC ACID(Non-covalent)
PLM.3: 1 residues within 4Å:- Chain A: P.139
Ligand excluded by PLIPPLM.4: 4 residues within 4Å:- Chain A: R.120, W.123, L.124, A.127
Ligand excluded by PLIPPLM.5: 5 residues within 4Å:- Chain A: A.17, V.18, G.84, L.88, L.91
Ligand excluded by PLIPPLM.6: 9 residues within 4Å:- Chain A: H.8, E.11, W.75, I.79
- Chain C: H.7, L.71, W.75
- Ligands: PLM.7, PLM.13
Ligand excluded by PLIPPLM.7: 9 residues within 4Å:- Chain A: H.7, H.8, L.71, W.75
- Chain B: E.11, W.75, I.79
- Ligands: PLM.6, PLM.13
Ligand excluded by PLIPPLM.10: 4 residues within 4Å:- Chain A: K.9
- Chain B: F.80, F.81, A.135
Ligand excluded by PLIPPLM.11: 3 residues within 4Å:- Chain B: W.123
- Ligands: PLM.14, LMT.16
Ligand excluded by PLIPPLM.12: 1 residues within 4Å:- Chain B: F.137
Ligand excluded by PLIPPLM.13: 10 residues within 4Å:- Chain B: H.7, H.8, K.9, L.71, W.75
- Chain C: E.11, V.12, I.79
- Ligands: PLM.6, PLM.7
Ligand excluded by PLIPPLM.14: 4 residues within 4Å:- Chain B: A.119, W.123
- Ligands: JUQ.8, PLM.11
Ligand excluded by PLIPPLM.15: 4 residues within 4Å:- Chain B: V.18, G.84, L.88, L.91
Ligand excluded by PLIPPLM.19: 5 residues within 4Å:- Chain B: K.9
- Chain C: F.80, F.81, L.131, A.135
Ligand excluded by PLIPPLM.20: 6 residues within 4Å:- Chain B: L.24
- Chain C: R.120, W.123, L.124, V.126, A.130
Ligand excluded by PLIPPLM.21: 2 residues within 4Å:- Chain C: R.120, W.123
Ligand excluded by PLIPPLM.22: 3 residues within 4Å:- Chain C: P.139, L.142, R.143
Ligand excluded by PLIPPLM.23: 1 residues within 4Å:- Chain C: F.137
Ligand excluded by PLIP- 1 x LMT: DODECYL-BETA-D-MALTOSIDE(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Munck Af Rosenschold, M. et al., Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma. J.Med.Chem. (2019)
- Release Date
- 2019-08-28
- Peptides
- Leukotriene C4 synthase: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
C - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.35 Å
- Oligo State
- homo-trimer
- Ligands
- 3 x JUQ: (1~{S},2~{S})-2-[5-[cyclopropylmethyl(naphthalen-1-yl)amino]-4-methoxy-pyrimidin-2-yl]carbonylcyclopropane-1-carboxylic acid(Non-covalent)
- 3 x NI: NICKEL (II) ION(Non-covalent)
- 16 x PLM: PALMITIC ACID(Non-covalent)
- 1 x LMT: DODECYL-BETA-D-MALTOSIDE(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Munck Af Rosenschold, M. et al., Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma. J.Med.Chem. (2019)
- Release Date
- 2019-08-28
- Peptides
- Leukotriene C4 synthase: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
C - Membrane
-
We predict this structure to be a membrane protein.